The Epithelial–Mesenchymal Transition Influences the Resistance of Oral Squamous Cell Carcinoma to Monoclonal Antibodies via Its Effect on Energy Homeostasis and the Tumor Microenvironment

• Published in: Cancers Vol. 13; no. 23; p. 5905
• Main Authors: Bai, Yunpeng, Sha, Jingjing, Okui, Tatsuo, Moriyama, Ichiro, Ngo, Huy Xuan, Tatsumi, Hiroto, Kanno, Takahiro
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 24.11.2021; MDPI
• Subjects: Antigens; Cancer therapies; Chemotherapy; Drug resistance; Energy balance; Energy metabolism; Energy resources; Epidermal growth factor; Esophageal cancer; Genes; Homeostasis; Intolerance; Kinases; Ligands; Lymphocytes T; Medical prognosis; Mesenchyme; Metastases; Metastasis; Monoclonal antibodies; Oral carcinoma; Oral squamous cell carcinoma; Pembrolizumab; Proteins; Review; Stem cells; Toxicity; Tumor microenvironment; epithelial–mesenchymal transition; pembrolizumab; nivolumab; chemotherapeutic monoclonal antibodies; cetuximab; oral squamous cell carcinoma; tumor microenvironment
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13235905

Oral squamous cell carcinoma (OSCC) is a major type of cancer that accounts for over 90% of all oral cancer cases. Recently developed evidence-based therapeutic regimens for OSCC based on monoclonal antibodies (mAbs), such as cetuximab, pembrolizumab, and nivolumab, have attracted considerable attention worldwide due to their high specificity, low toxicity, and low rates of intolerance. However, the efficacy of those three mAbs remains poor because of the low rate of responders and acquired resistance within a short period of time. The epithelial–mesenchymal transition (EMT) process is fundamental for OSCC growth and metastasis and is also responsible for the poor response to mAbs. During EMT, cancer cells consume abundant energy substrates and create an immunosuppressive tumor microenvironment to support their growth and evade T cells. In this review, we provide an overview of the complex roles of major substrates and signaling pathways involved in the development of therapeutic resistance in OSCC. In addition, we summarize potential therapeutic strategies that may help overcome this resistance. This review aims to help oral oncologists and researchers aiming to manage OSCC and establish new treatment modalities.